论文信息 - Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial - 字舞流文

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

S. Corti | M. Pane | E. Mercuri | F. Muntoni | L. Servais | M. Scoto | O. Boespflug-Tanguy | A. Vanlander | Claudio Bruno | G. Baranello | V. Straub | N. Deconinck | S. Tauscher‐Wisniewski | F. Magri | M. Pedemonte | V. Schembri | A. Lavrov | L. Antonaci | A. Defeldre | E. Pagliano | N. Mendonça | A. Jollet | F. Abel | R. M. Lofra | R. Masson | G. Coratti | V. Parente | R. D. Sanctis | R. Zanin | M. Arnoldi | G. Comi | A. Daron | N. Brolatti | A. Seferian | H. V. Ruiten | M. Sole | L. Buscemi | A. Mandelli | S. Morando | D. Chand | V. Tahon | S. Tachibana | H. Ouyang | L. Edel | F. Farra | O. Schneider | M. Pera | S. Lucia | S. Mouffak | E. D. Vos | A. Govoni | M. Foa | A. Jonas | K. Groves | E. Thompson

[1] J. Mendell,et al. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy , 2021, JAMA neurology.

[2] R. Finkel,et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial , 2021, The Lancet Neurology.

[3] C. Zaidman,et al. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series. , 2020, The Journal of pediatrics.

[4] G. Kullak-Ublick,et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. , 2020, Journal of hepatology.

[5] R. Finkel,et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review , 2020, Orphanet Journal of Rare Diseases.

[6] J. Mendell,et al. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. , 2019, Journal of neuromuscular diseases.

[7] Craig McDonald,et al. Natural history of infantile‐onset spinal muscular atrophy , 2017, Annals of neurology.

[8] Brian K. Kaspar,et al. Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[9] R. Finkel,et al. Developmental milestones in type I spinal muscular atrophy , 2016, Neuromuscular Disorders.

[10] W. Chung,et al. Observational study of spinal muscular atrophy type I and implications for clinical trials , 2014, Neurology.

[11] W. Chung,et al. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) , 2011, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[12] R. Finkel,et al. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability , 2010, Neuromuscular Disorders.

[13] Mercedes Onis,et al. WHO Child Growth Standards based on length/height, weight and age , 2006, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[14] A. Lartey,et al. Assessment of Gross Motor Development in the who Multicentre Growth Reference Study , 2004 .

[15] B. Wirth,et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2 , 2002, Genetics in Medicine.

[16] D. McCarty,et al. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis , 2001, Gene Therapy.

[17] B. Byrne,et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.